The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

Akin Akinc(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Kevin Fitzgerald(Alnylam Pharmaceuticals (United States)), Muthusamy Jayaraman(Alnylam Pharmaceuticals (United States)), Scott Barros(Alnylam Pharmaceuticals (United States)), Steven M. Ansell(Acuitas Therapeutics (Canada)), Xinyao Du(Acuitas Therapeutics (Canada)), Michael J. Hope(Acuitas Therapeutics (Canada)), Thomas D. Madden(Acuitas Therapeutics (Canada)), Barbara L. Mui(Acuitas Therapeutics (Canada)), Sean C. Semple(Acuitas Therapeutics (Canada)), Ying K. Tam(Acuitas Therapeutics (Canada)), Marco A. Ciufolini(University of British Columbia), Dominik Witzigmann(University of British Columbia), Jayesh A. Kulkarni(University of British Columbia), Roy van der Meel(University of British Columbia), Pieter R. Cullis(University of British Columbia Hospital)
Nature Nanotechnology
December 1, 2019
Cited by 1,549Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis